The First Approved Treatment for Low Desire After Menopause

Persistently low sexual desire that causes real distress, known clinically as hypoactive sexual desire disorder, affects a meaningful share of postmenopausal women, yet until recently no medication was approved for them specifically. This trial randomly assigned 949 postmenopausal women with the condition to a daily non-hormonal medication, flibanserin, or placebo for 24 weeks. Women taking flibanserin reported more satisfying sexual encounters and greater improvement in desire and related distress than those on placebo, with dizziness, sleepiness and nausea the most common side effects. A companion trial in a similar population found a similar direction of benefit but with weaker, underpowered results, an honest inconsistency worth knowing rather than glossing over. Together, this body of evidence became the basis for the medication's expanded approval for postmenopausal women in December 2025, more than a decade after this trial and a decade after its original approval for younger women. For a woman who has quietly written off her own low desire as an inevitable part of this stage, it confirms that a real, evidence-based, FDA-approved option now exists to discuss with a doctor.